Navigation Links
Resverlogix Completes Patient Recruitment for ASSERT Trial
Date:2/8/2010

Full enrollment occurs five months ahead of schedule

TSX Exchange Symbol: RVX

CALGARY, Feb. 8 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic. At this rate we could be seeing the final dosed patient in May of 2010. In the second half of 2010, we look forward to being able to share the results from the trial, which will mark yet another major milestone in the development of our oral therapeutic for the treatment of atherosclerosis," explained Donald J. McCaffrey, President and CEO of Resverlogix Corp.

Once completed, the randomized, double-blind, placebo-controlled, multi-centered US study will have administered RVX-208 to approximately 280 patients with stable coronary artery disease for a period of 13 weeks. The primary objective of this study is to determine if RVX-208 will produce an increase in plasma apolipoprotein A-I (ApoA-l) levels compared to placebo group after three months of dosing. The secondary objectives are to examine the safety and tolerability of RVX-208, to compare the dose and time response relationships for ApoA-l over time as well as to examine key reverse cholesterol markers involved with HDL functionality.

In other news today, Donald J. McCaffrey will be providing an updated corporate overview during the BIO CEO & Investor conference. Mr. McCaffrey's presentation will take place in the Basildon room at the Waldorf-Astoria, New York City, from 4:00 pm - 4:25 pm EST.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
2. Resverlogix Presenting at Biotech Showcase
3. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
4. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
5. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
6. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
7. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
8. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
9. Resverlogix Provides Quarterly Update
10. Resverlogix Board of Directors Update
11. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, Inc., a leading ... a paper published this week in the scientific journal Viruses ( http://www.mdpi.com/1999-4915/7/6/2763 ), ... currently used to detect the Ebola virus. Noblis worked with the Department of ...
(Date:6/30/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... on the development of autologous cell therapies, announced today ... clinical trial of RCT-01, being tested for the ... enrolled and their tissue biopsy sent for processing ... of non-bulbar dermal sheath (NBDS) cells isolated from ...
(Date:6/29/2015)... ... June 30, 2015 , ... This cutting edge standard making is a ... 12 distinct peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter that lets ... the NIR range. Previous spectrophotometer calibration standards, such as those made from didymium glass ...
(Date:6/29/2015)... 2015  AACC, a global scientific and medical ... medicine, is pleased to announce that the impact ... has increased to 7.9 in the 2014 Thomson ... Clinical Chemistry in the top 3% of ... of the research it publishes on laboratory medicine ...
Breaking Biology Technology:Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... 5 Dynamic Alert,Limited (OTC Bulletin Board: DYMC) ... its target markets for its pharmaceutical product line-up. ... for enhancing rapid onset,through oromucosal absorption, topical applications, ... internal use. Some products will have,specific uses, while ...
... Dec. 5 Early clinical experience with the FDA,cleared ... of ultrasound guided cryoablation to completely eradicate,small, unifocal Invasive ... study was presented at the 94th Scientific Assembly and ... November 29 -,December 5, 2008. , ...
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext ... Agreement with the http://www.senesco.com ("Harris Moran") has ... recently announced corporate restructuring. , ... parent company, Limagrain, restructured its vegetable seed operations and ...
Cached Biology Technology:Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 2Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 3Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... , In most tissues, cells are surrounded by an ... and fibronectin. The ECM plays an important role in ... other cell surface receptors, activating signaling pathways that regulate ... Written and edited by experts in the field, ...
... Elsevier, the world-leading publisher of scientific, technical ... that its 2012 eBook Frontlist collections are available ... platform for scientific content. This release marks a ... the eBook collection on SciVerse ScienceDirect. The 2012 ...
... Much of the body,s chemistry is controlled by the brain ... published recently in Developmental Cell , a team of scientists ... the exact structure of one crucial brain area in which biochemical ... from there to the body. In the process, they discovered a ...
Cached Biology News:Elsevier announces new 2012 Frontlist eBooks collection on SciVerse ScienceDirect 2A hormone ensures its future 2
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
A trigger solution for Flashlight labeled materials....
Biology Products: